DNA double-strand breaks (DSBs) can cause genetic mutations that activate oncogenes, inactivate tumor suppressors, and change the levels or functions of ‘modifier’ proteins, which determine chemosensitivity or tumor progression, thus potentially increasing an organism’s susceptibility to cancer and a myriad of other diseases. To defend themselves against the deleterious effects of DSBs, eukaryotic organisms employ an intricate DNA damage response (DDR) pathway to detect DNA lesions, arrest the cell cycle until damaged DNA is repaired, and to induce cell death if the lesions are overwhelming. Thus, efficient induction of the DDR and cell death pathways after DNA damage is crucial in cellular defenses against malignant transformation.

One of the most important proteins in the DDR pathway is histone H2AX. Results from H2AX knockout studies in mice indicate that loss of one or two copies of the H2AX gene compromises genomic integrity and DDR efficiency and increases tumor formation in a p53-null background. Furthermore, H2AX phosphorylation status has been shown to determine whether cells repair the damaged DNA to survive or undergo apoptosis. In response to DNA DSBs, ATM and/or DNA-PK phosphorylate histone H2AX at Ser139 to form γ-H2AX. Formation of γ-H2AX foci on DSB sites is the earliest and the critical event in the DDR pathway. H2AX not only serves to indicate the localization of DNA lesions, but its phosphorylation and subsequent ubiquitylation by the RNF8 ubiquitin ligase are required for DNA damage signal amplification and the accumulation of numerous DDR proteins at the sites of DSBs to form the so-called ionizing radiation-induced foci.

Another important determinant of genomic integrity and cellular response to DNA damage is the level of intracellular reactive oxygen species (ROS), which is tightly regulated through the coordinated activities of cellular pro-oxidants and antioxidants. Intracellular ROS can act as a cellular toxicant or a signaling molecule, depending on its concentration and localization. Intracellular ROS is primarily generated through aerobic metabolism or through a specialized group of enzymes, collectively known as the NAD(P)H oxidases (Noxes). Human cells possess seven distinct Nox enzymes including: Nox1-5 and Duox1-2 (reviewed in 13–15). Among them is Nox1 that is expressed in epithelial cells and non-phagocytes. At the molecular level, Nox1 associates with the membrane subunit p22phox, which is necessary for enzymatic activity. Nox1 is activated by forming a complex with the cytoplasmic activators p47phox and p67phox (and their non-phagocytic homologs NoxO1 and NoxA1) and the small GTPase Rac1. The primary ROS produced by Nox1 is O2•−, although H2O2 is thought to be the most important signaling molecule in Nox1 signal transduction. Importantly, Nox1-induced ROS has been implicated in oncogenic signaling in Ras-transformed NIH3T3 cells, where depletion of H2O2 suppressed uncontrolled cell growth.

DNA damage from various sources has been shown to increase ROS levels. DNA damage-induced ROS is important in the regulation of cell death and survival.
partly due to its ability to regulate p53 activity. In turn, the tumor suppressor p53 has been demonstrated to regulate basal and DNA-damage-induced ROS levels. However, the exact mechanism by which DNA damage induces ROS and the involvement of other DDR proteins in ROS generation remain to be elucidated.

In this study, we demonstrate that DNA damage induces ROS through histone H2AX, Nox1, and Rac1. DNA damage-induced ROS is significantly increased by H2AX overexpression and reduced by its knockdown. ROS induction by histone H2AX expression can be abrogated by treatment of cells with the Nox inhibitor diphenyliodonium chloride (DPI), expression of a dominant negative Rac1 mutant (Rac1N17), and knockdown of Nox1. Recent studies have demonstrated that 14-3-3zeta binds to NoxA1, resulting in the inactivation of Nox1 by sequestration of NOXA1 from Nox1 in the plasma membrane. More recent proteomic analysis indicated that H2AX constitutively binds to 14-3-3zeta in a normally growing human hepatocellular carcinoma cell line. We found that 14-3-3zeta forms a complex with NOXA1 in control U2OS cells, and that H2AX overexpression reduces this interaction. We also found that DNA damage generates an oscillation of increased ROS, and that suppression of DNA damage-induced ROS by the antioxidant N-Acetyl-L-Cysteine (NAC) reduces apoptosis. Our results point to a novel interaction between H2AX and Nox1, which regulates ROS levels and apoptosis after DNA damage.

Results

ROS induction after DNA damage in mammalian cells. DNA damage has been shown to stimulate the production of ROS in cell cultures. We first examined how different DNA-damaging agents induce ROS in different mammalian cell lines. Sub-confluent U2OS (human osteosarcoma) and HBL100 (human mammary epithelial) cells were seeded onto 96-well plates, treated with neocarzinostatin (NCS, a radiomimetic reagent), doxorubicin, or hydroxyurea (HU) for 20 min to 5 h, and ROS levels were quantified using the fluorogenic dye DCFH-DA and a fluorescence microplate reader. Although there were some differences in the amplitudes and kinetics of ROS induced by NCS, doxorubicin, and HU, all three compounds induce ROS biphasically in this time course, with an early ROS burst occurring within 2 h of DNA damage, a transient drop within 2–3.5 h, followed by a second ROS burst occurring within 3.5–5 h of DNA damage (Figure 1a).

ROS induces cell death after DNA damage. We tested if DNA-damage-induced ROS is important for the induction of
To study this, we suppressed the second NCS-induced ROS burst by adding the antioxidant NAC 2 h after NCS treatment, and quantified total cell death 24 h later. NCS induces DNA damage through the generation of free radicals, resulting in the activation of DDR components, such as ATM, H2AX, p53, and DNA-PK. As expected, adding NAC immediately after NCS addition prevented both ROS production and the DNA-damage-induced activation of DDR proteins (data not shown). Meanwhile, adding NAC 2 h after NCS treatment abrogated the second burst of NCS-induced ROS without interfering with DDR activation (Figure 1b), allowing us to more accurately determine the effect of NCS-induced ROS on apoptosis induction. We found that suppression of the second NCS-induced ROS burst by NAC treatment significantly reduces cell death (Figure 1c). These results indicate that, once DDR proteins are activated immediately after DNA damage, an oscillation of increased ROS is generated, and this is crucial for subsequent cell death. Of note, the second burst of ROS induction is much higher than the first when cells are treated with NCS (Figure 1a), although phosphorylation of H2AX and ATM at Ser1981 are significantly lower than those observed within 20 min after treatment (Figure 2).

DNA damage increases levels of protein and phosphorylation of histone H2AX. It has been well illustrated that histone H2AX is involved in DNA stress pathways and is phosphorylated by ATM in response to cell stress, and that the phosphorylated form of H2AX (γ-H2AX) colocalizes to sites of DNA lesions. We found that, when the U2OS human osteosarcoma cell line and the HBL100 human mammary epithelial cell line are treated with NCS, levels of histone H2AX protein are markedly increased within 20–45 min after treatment (nearly 2–3-fold in U2OS and HBL100 cells, respectively; Figure 2 and Supplementary Figure 1). An increase in H2AX protein levels was also observed when cells were treated with doxorubicin (data not shown). When γ-H2AX levels were normalized to H2AX protein levels through densitometric analysis, we found that NCS treatment did not increase H2AX phosphorylation in U2OS or HBL100 cells (Supplementary Figure 1). Of note, upregulation of H2AX after NCS treatment preceded that of ROS (Figures 1 and 2), raising the possibility that H2AX may mediate ROS induction after DNA damage.

Histone H2AX mediates ROS induction after DNA damage. By using U2OS and HBL100 cell lines, we established stable cell lines either overexpressing Flag-tagged H2AX (Flag-H2AX), or expressing a tet-regulatable H2AX shRNA in which the level of endogenous H2AX is decreased in the presence of doxycycline in cell culture. Using these cell lines, we tested whether levels of H2AX determine the basal or NCS-induced levels of ROS. Levels of Flag-H2AX and decreased levels of endogenous H2AX by shRNA were confirmed by immunoblot analysis. We found that, when H2AX was highly expressed in U2OS and HBL100 cells, basal levels of ROS were significantly increased, and that ROS was further produced when cells were treated with NCS, when compared with the levels of ROS in control U2OS and HBL100 cells (Figures 3a and b).

Next, we knocked down endogenous histone H2AX by treating cells expressing tet-regulatable H2AX shRNA with doxycycline. Although basal levels of ROS did not change when endogenous H2AX was knocked down, induction of ROS by NCS was significantly attenuated (Figures 3c and d). Together, the results from our H2AX overexpression and knockdown experiments provide strong evidence that H2AX can regulate ROS levels.

Histone H2AX upregulates DNA-damage-induced ROS through Nox1 and Rac1. We investigated the mechanism by which histone H2AX increased the levels of ROS after DNA damage. Several proteins and pathways have been implicated in ROS production in mammalian cells. Among them are the NADPH oxidase (Nox) family of proteins: membrane-associated, multimeric flavin-containing enzymes that catalyze the reduction of oxygen using electrons from NADPH. A number of regulatory subunits have been identified for the Nox proteins, including p22 phox, NoxO1, Nox1, NoxA1, and Rac1. When parental U2OS cells were treated with NCS for 5 h, levels of ROS increased about 1.5-fold, whereas U2OS cells expressing Flag-H2AX exhibited higher induction of ROS compared with untreated U2OS cells expressing Flag-H2AX (~1.8-fold, Figure 4a). However, when parental and Flag-H2AX expressing U2OS cells were treated with NCS in the presence of 0.5 μM diphenyldichloroimid acid (DPI, a broad-spectrum inhibitor of flavin-containing enzymes including Noxes), the increase in ROS was almost completely inhibited.

Inhibition of NCS-induced increases in ROS by DPI was also observed in HBL100 cells (Figure 4b). Levels of ROS in control HBL100 cells were increased ~3.5-fold with NCS treatment. When Flag-H2AX was expressed in HBL100 cells, induction of ROS was further increased ~4.3-fold compared
Figure 3  Histone H2AX increases basal and DNA damage-induced ROS. Overexpression of Flag-H2AX increased basal and NCS-induced ROS in U2OS (a) and HBL-100 (b) cells, whereas inducible H2AX knockdown reduces NCS-induced ROS in HCT-116 (c) and HBL100 (d) cells. Immunoblot analysis was performed at 5 h after NCS treatment. **Flag-tagged H2AX, *endogenous H2AX.

Figure 4  H2AX increases ROS through Nox1/Rac1 pathway. Control U2OS cells (a, white bar), Flag-H2AX U2OS cells (a, black bar), control HBL100 cells (b, white bar), and Flag-H2AX HBL100 cells (b, black bar) were treated with NCS (0.5 μg/ml, 5 h) with or without the Nox-inhibitor, DPI (0.5 μM) and fold-induction of ROS was measured. (c) Vector control cells or Flag-H2AX U2OS cells were transiently transfected with an indicated plasmid with a control vector for 12 h, followed by NCS treatment (0.5 μg/ml) for 5 h. Levels of ROS were measured in more than three independent experiments. (d) Levels of proteins were immunoblotted to confirm expression or knockdown of indicated proteins. (e) Expression of H2AX inhibited coimmunoprecipitation of 14-3-3zeta with NOXA1. U2OS cells were transfected with the indicated plasmids, followed by GST-pulldown of 14-3-3zeta. **Flag-tagged H2AX, *endogenous H2AX.
with untreated HBL100 cells expressing Flag-H2AX (Figure 4b). Two different concentrations of DPI (0.2 and 0.5 μM) were examined; both concentrations inhibited ROS production in control HBL100 cells and HBL100 cells expressing Flag-H2AX. Of note, DPI did not completely inhibit ROS production in these cell lines at these concentrations, which suggests that Nox-independent mechanisms also produce ROS in HBL100 cells.

These results strongly suggest that H2AX induces ROS by activating Nox protein(s) when cells are exposed to DNA-damaging agents. We then sought to identify the Nox enzyme that mediates H2AX-induced ROS. Nox1 and Nox4 are the two most ubiquitous Nox enzymes in epithelial and endothelial cells, whereas Nox2 is highly expressed in phagocytes. It has been demonstrated that Nox1 activity is Rac1-dependent, whereas Nox4 activity is not. Based on these observations, we used the pSilencer4.1-CMV-neo vector to generate a plasmid expressing Nox1 shRNA and examined the effect of Nox1 knockdown on DNA-damage-induced ROS in H2AX overexpressing cells. In vector control U2OS cells, NCS treatment increased ROS ~1.7-fold. Basal levels of ROS in U2OS cells expressing Flag-H2AX were higher (~2.0-fold) than U2OS vector control cells; this was further increased ~4.4-fold when cells were treated with NCS. We found that Nox1 knockdown with shRNA similarly reduced both basal and DNA-damage-induced ROS in U2OS cells expressing Flag-H2AX to ~1.5-fold (Figure 4c). Of note, this is still higher than control, suggesting that DNA damage also induces ROS through pathways that do not involve the H2AX-Nox1 axis (see Figure 5). Consistent with these observations, when Nox1 is knocked down in NCS-treated parental U2OS and 293T cells, ROS were still produced (Supplementary Figure 4). On the other hand, when Nox4 is knocked down in U2OS cells expressing Flag-H2AX, no significant decrease in the levels of basal and NCS-induced ROS was observed (Figure 4c).

To further investigate whether the Nox1 pathway was involved in H2AX-mediated ROS induction, we introduced a dominant negative form of Rac1 (Rac1N17) in parental and Flag-H2AX-overexpressing U2OS cells to inhibit the Rac1 pathway and ultimately increases intracellular levels of ROS. H2AX can also induce ROS and apoptosis by the alternative pathways that are usually inhibited by Nox1. When Rac1N17 was co-expressed in Flag-H2AX U2OS cells, ROS were still produced (Supplementary Figure 2). Levels of the proteins studied in these experiments were shown in Figure 4d.

We then explored the mechanisms of how increased H2AX increases the levels of ROS. Recent studies have demonstrated that 14-3-3zeta binds to NoxA1, resulting in the inactivation of Nox1 by sequestration of NoxA1 from Nox1 in the plasma membrane. Interestingly, more recent proteomic analysis indicated that H2AX constitutively binds to 14-3-3zeta in a normally growing human hepatocellular carcinoma cell line. It is therefore possible that DNA damage-induced H2AX titrates out the 14-3-3zeta from Nox1, thus potentiating the formation of an active Nox1/NoxA1 complex. We found that GST-tagged 14-3-3zeta co-immunoprecipitates a complex containing HA-tagged NoxA1 in control U2OS cells. However, this complex was not detected in Flag-H2AX U2OS cells (Figure 4e). Thus, we postulate that overexpression of H2AX causes NoxA1 to be released from 14-3-3zeta resulting in an increase in ROS levels.

It has been illustrated that EGF stimulation or oncogenic signals such as K-RasVal12 upregulates Nox1 mRNA. In light of this, we tested whether the activation of Nox1 signaling by H2AX occurs through an upregulation in Nox1 protein levels. However, we found that neither H2AX overexpression nor H2AX depletion by shRNA causes a significant change in Nox1 protein levels (not shown), suggesting that the activation of Nox1 pathway by H2AX is not through an increase in the levels of Nox1 protein.

These results indicate that the increased level of H2AX in DNA-damaged cells promotes the activation of the Nox1/Rac1 pathway and ultimately increases intracellular levels of ROS.

H2AX-mediated apoptosis is inhibited by Rac1N17. It has been shown that high levels of ROS can induce apoptosis. As our results demonstrate that expression of H2AX increases the levels of ROS, we tested whether H2AX can induce apoptosis without DNA stress. Constitutive levels of apoptosis were determined in control and Flag-H2AX U2OS cells. As shown in Figure 6a, levels of apoptosis are
significantly elevated in U2OS cells stably expressing Flag-H2AX. Increased levels of apoptosis were also studied in 293T and U2OS cells transiently co-expressing Flag-H2AX and HA-Rac1N17 (Figures 6b and c). In both cell types, expression of Flag-H2AX significantly increased the level of apoptosis, whereas co-expression of HA-Rac1N17 reduced Flag-H2AX-induced apoptosis. Inhibition of apoptosis by HA-Rac1N17 was less effective in 293T cells than in U2OS cells, suggesting that regulation of apoptosis by H2AX/Rac1 may be determined by cell context.

Discussion

DNA damage from various sources has been shown to increase intracellular levels of ROS, which in turn regulates cell death or senescence through p53-dependent and -independent mechanisms. Induction of cell death or senescence is one of the most important defense responses against malignant transformation. A well-characterized pathway of ROS production and regulation is through the p53 tumor suppressor and the mitochondria. However, the detailed mechanism of ROS generation after DNA damage remains to be uncovered and the roles of other DDR proteins in ROS regulation still need to be investigated.

Our studies indicate that DNA damage-induced apoptosis is reduced when the second burst of DNA damage-induced ROS is suppressed by treatment of cells with the antioxidant NAC. Autophosphorylation of ATM at Ser1981 occurred within 20 min of NCS treatment. On the other hand, an increase in H2AX protein and its phosphorylation was initially observed within 20 min after NCS treatment and reached its peak within 45 min in U2OS and HBL100 cell lines. We found

Figure 6  High levels of H2AX induces apoptosis without DNA damage, which is decreased by Rac1N17. (a) U2OS cells stably expressing Flag-H2AX show constitutive apoptosis without DNA damage, compared with vector control cells. 293T (b) or U2OS (c) cells were transfected with expression vectors of Flag-H2AX, HA-Rac1N17 or both for 48 h, and apoptosis was compared with that of vector control cells. A bar graph represents fraction of apoptotic cells.
that the second burst of ROS induction (3.5–5 h after NCS in U2OS and HBL100 cells, Figure 1a) was not accompanied by increased phosphorylation of ATM and H2AX (Figure 2, data not shown), indicating that the first burst, but not the second, of ROS induction within the first 20–45 min after DNA damage require the activation/phosphorylation of DDR proteins and the resultant apoptotic phenotype.

Although the importance of histone H2AX in the accumulation of DDR and repair proteins at sites of DSBs has been well established, the role of H2AX in other signaling pathways is not fully understood. In this study, we established a novel pathway that DNA damage increases intracellular ROS levels through histone H2AX, Rac1, and Nox1. We found that levels of intracellular ROS are increased by not only DNA damage but also H2AX overexpression. Given that DNA damage increases endogenous levels of ROS, our results suggest a signaling loop between ROS production and increase in H2AX to amplify the signal causing apoptosis.

In the cell lines we tested, DNA damage induces ROS biphassically, with an early burst occurring within 45 min of DNA damage induction and a late second burst occurring within 5 h. The late burst of ROS induced by NCS can be inhibited by either Nox1 shRNA or Rac1N17 (see Supplementary Figure 3). However, the early burst of ROS is not inhibited by Nox1 shRNA or Rac1N17, suggesting that whereas the late burst of ROS is generated through the Nox1/Rac1 axis, the early burst is induced through DDR components. Furthermore, when Rac1/Nox1 is inhibited, cells still produce certain levels of ROS (Figure 4c), suggesting that production of ROS is at least in part amplified in Rac1/Nox1-independent manner.

We found that overexpression or knockdown of H2AX does not significantly change Nox1 protein levels (Figure 4, not shown), suggesting that H2AX does not increase ROS levels by augmenting Nox1 protein expression or stability. However, communoprecipitation assays indicate that the Nox1 activator NoxA1 is released from 14-3-3zeta in cells expressing high levels of H2AX. As it has been shown that binding of 14-3-3zeta to NoxA1 complex is inhibitory for Nox1 activity, we propose a model where increased H2AX binds and sequester cellular 14-3-3zeta, resulting in the release of NoxA1 and the activation of Nox1 complex.

There are some potential links between our findings and human diseases. Constitutive production of superoxide was induced upon Ras transformation in NIH3T3 cells, and depletion of its dismutated metabolite H2O2 suppressed the uncontrolled growth of Ras-transformed cells. Significantly, introduction of Nox1 siRNA into K-RasVal12-transformed NRK (normal rat kidney) cells was shown to block their anchorage-independent growth and induced morphological reversion, supporting the idea that Nox1-mediated production of ROS has crucial roles in cell transformation. Our observation that H2AX can activate Nox1/Rac1-mediated production of ROS raises the possibility that H2AX may be involved in cell transformation induced by Ras and other oncogenes.

It has been shown recently that the status of H2AX phosphorylation is crucial to determine whether cells will survive or undergo apoptosis after DNA damage. Because ROS can also activate both cell survival and apoptotic pathways depending on its concentration and localization, regulation of ROS by H2AX may be one mechanism to determine cell survival or apoptosis after DNA insults. Therefore, elucidating the relationship between H2AX phosphorylation status, ROS regulation, and cell fate after DNA damage may provide understanding of DDR regulation relevant to the inhibition of cancer growth and progression.

Materials and Methods

Cell culture. U2OS, HBL100, HeLa, and HCT-116 cells were maintained in Dulbecco’s Modified Eagle Medium ( Gibco, Grand Island, NY, USA), supplemented with 10% fetal bovine serum (Invitrogen, Grand Island, NY, USA) or cosmic calf serum (HyClone, Logan, UT, USA). To induce DNA damage, cells were treated with 0.5–1 μg/ml neocarzinostatin (Kayaku, Tokyo, Japan), 8.5 μM doxorubicin (Sigma, St. Louis, MO, USA), or 2 mM hydroxyurea (Sigma).

Plasmids and transfection. pSingle-ITS-shRNA vector (Clontech, Mountain View, CA, USA) was used to generate plasmids expressing tet-inducible H2AX shRNA with the target sequence 5’-TCGGAATTTGACGCTACAACTG-3’ or 5’-CAACAAGAAGAGCCGACATGG-3’, according to the manufacturer’s instructions. Briefly, shRNA-encoding oligonucleotides were synthesized, annealed, and cloned into XhoI/HindIII sites of the vector. pcDNAS-Flag-H2AX was generated by subcloning Flag-H2AX from pEF into the EcoRI/NcoI sites of pcDNA3. pEF-HA-Rac1WT/Rac1N17 was generated by PCR amplification from a complementary DNA library, followed by site-directed mutagenesis (Stratagene, Wilmington, DE, USA) and subsequent subcloning into a pEF vector. pEgfp-14-3-3zeta was purchased from Addgene (Cambridge, MA, USA). Nox1 shRNA was obtained from Drs. Barfi Botond (University of Iowa) and Hideki Sumimoto (Kyushu University, Japan). pSilencer4.1-CMV-Neo vector was used to generate plasmids expressing Nox1 and Nox4 shRNA with the target sequences 5’-CGAAGTGGATGATGAC-3’ (Nox1) and 5’-TTAGCTATGAGGTC-3’ (Nox4), according to the manufacturer’s instructions. Briefly, shRNA-encoding oligonucleotides were synthesized, annealed, and cloned into HindIII/BamHI sites of the vector. Transfections were performed with Fugene-6 or Fugene-HD (Roche Applied Science, Indianapolis, IN, USA), according to the manufacturer’s protocol.

Generation of stable cell lines. To generate stable H2AX-overexpression and tet-on-H2AX-knockdown cell lines, cells were first transfected with pcDNA3-Flag-H2AX and pSingle-ITS-H2AX-shRNA. Forty-eight to seventy-two hours after transfection, cells were reseeded at low density and stable transfectants were selected using neomycin at pre-optimized concentrations (1000 μg/ml for U2OS, 500 μg/ml for HCT116, and 1500 μg/ml for HBL100). Stable transfectants were cultured in neomycin-containing media until colonies become visible (after approximately 1–2 weeks in culture; media and neomycin) is changed and refreshed every 72 h. Colonies were trypsinized and transferred to 96-well or 48-well plates when they become visible, and both colonies and ‘pools’ of stable transfectants (a pool of the colonies that were not picked) were cultured for an additional 1–2 weeks. Stable transfectants were subsequently screened for H2AX overexpression and knockdown through western blot. Inducible H2AX knockdown was performed by culturing cells stably expressing pSingle-ITS-H2AX-shRNA in media containing 2 μM doxycycline (Sigma) for 24 h (HCT116) or 48 h (HBL100).

Immunoblot analysis and densitometry analysis. The following primary antibodies were purchased for immunoblot analysis: for H2AX protein (77835, Genetex, Irvine, CA, USA), α-tubulin (5286, Santa Cruz Biotechnology, Santa Cruz, CA, USA), β-actin (C-11, Santa Cruz Biotechnology), HA-probe (Y-11, Santa Cruz Biotechnology). Nox1 antibody (Abcam, Cambridge, MA, USA) was a generous gift from Dr. Andreana Simons. Cell extracts were prepared in EBC buffer (50 mM HEPES, pH 7.6, 250 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, pH 8.0, with mixed protease inhibitor (aprotinin, leupeptin, PMSF, Sigma). The secondary antibodies (Jackson Immuno-Laboratory, Mill Valley, CA, USA) were peroxidase-conjugated anti-mouse IgG (H + L), anti-rabbit IgG (H + L), or anti-goat IgG (H + L). Film (Hyblot, Denville Scientific, Metuchen, NJ, USA) was developed using ECL (Enhanced Chemiluminescence) reagent. The level of phosphorylation and expression of proteins were measured by densitometry using ImageJ software (National Institutes of Health) and the data were expressed as arbitrary units relative to band intensity of total protein or internal control.
Quantifying ROS levels. ROS levels were measured using 2,7-dichlorodihydrofluorescein diacetate oxidation (DCFH-DA, Sigma) and a fluorescence microplate reader. Briefly, cells were seeded onto 96-well plates (black/clear bottom, BD Biosciences, San Jose, CA, USA) at a density of 5000–10 000 cells per well. Twenty-four hours after seeding (at 40–70% density), cells were washed with PBS buffer (Invitrogen), treated with 100 μM DCFH-DA (diluted in DMEM – 1% FBS) for 1 h (at 37 °C, 5% CO2). Cells were then washed with PBS again, and treated with the DNA-damaging agents, NCS, doxorubicin, or hydroxyurea (diluted in PBS) for 20 min–5 h. DCF fluorescence is measured using a fluorescent microplate reader (Spectramax, Sunnyvale, CA, USA). Readings were done in triplicates, quadruplicates, or quintuplicates. ROS levels were normalized to cell number, which was measured using a fluorogenic DNA-binding dye (CyQuant fluorescence microplate reader). Because DCF fluorescence and CyQuant have the same excitation/emission spectrum, we stained cells with DCFH-DA and CyQuant in different (exact replicate) wells. Error bars represent the average standard error of all the samples in a single experiment.

Cell death assays. Apoptosis was quantified using the Annexin V-FITC Apoptosis Detection Kit (Calbiochem, San Diego, CA, USA) and a FACScalibur flow cytometer (BD Biosciences), according to the manufacturer’s instructions. Twenty-four hours after seeding, NCS was added to cell culture media. NAC (Sigma) was added 2 h after NCS addition, and Annexin-V-FITC assays were performed 24 h later. Apoptosis of 293T and U2OS cells after transient transfection of Flag-H2AX/pcDNA3 or HA-Rac1N17/pEF was determined at 48 h.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. We thank Drs. Banfi Botond (University of Iowa) and Hideki Sumimoto (Kyushu University, Japan) for sharing Nox1 cDNA. This work was supported in part by NIH Grants K01CA134941 (ALS), R01CA133114 (DRS), and R01CA79892, R01CA90631, Susan G Komen Breast Cancer Research Fund and Avon Breast Cancer Fund (TO).

1. Bassing CH, Att FW. The cellular response to general and programmed DNA double strand breaks. DNA Repair 2004; 3: 781–796.
2. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433–439.
3. Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair 2004; 3: 959–967.
4. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003; 114: 359–370.
5. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG. Tyrosine dephosphorylation in vivo DNA double-strand breaks.
6. Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under the Creative Commons Attribution-No Commercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/